



**Missed a Session?**

Listen to any session synchronized with the presentations

- Buy individual tracks or the entire conference

**Innovation Corridor 2006 Online Listing**

Print

The list below includes the posters being presented at BIO 2006 Innovation Corridor Posters

You may click the link to read the abstracts for the posters being presented. All abstracts were submitted by the presenting organizations. BIO is not responsible for content.

Click on header to sort list.

22

22

(Abstract Letter) / Poster Title	Organization	Display Day / Display Time	Category
(A10) The Institute for Collaborative Biotechnologies: A Powerful Alliance between Academia, Industry, and the Army Abstract	Institute for Collaborative Biotechnologies	Monday, April 10, 9:00 AM - 12:00 PM	
(A3) Development of Novel Thermostable Enzymes to Improve Bioethanol Production Abstract	Lucigen Corporation	Monday, April 10, 9:00 AM - 12:00 PM	Agriculture/For
(A22) Physiological Hydrophobic Interaction Chromatography: A New Technique for Process Applications Abstract	Pall Life Sciences	Monday, April 10, 9:00 AM - 12:00 PM	Bio
(A15) Value-added marine oils from Australia Abstract	Deep Sea Oils Pty Ltd	Monday, April 10, 9:00 AM - 12:00 PM	Nut
(A11) Tandem Repeats of Recombinant Angiotensin-I Converting Enzyme Inhibitory Peptide Expressed in Escherichia	Kobe University	Monday, April 10, 9:00 AM - 12:00 PM	Bio

Abstract Letter: B 19

Display Date/Time: Monday, April 10, 1:00 PM - 4:00 PM

Title: New Prospective for MarkPap Technology for Cervical Cancer Control

[Print Abstract!](#)

Author: Dr. Olivera Markovic

Organization: BioSciCon, Inc

Category: Cancer

Stage of Development: Product in Development

Co-Author1: Dr. Nenad Markovic/BioSciCon

Co-Author3: Dr. David Hankins/John Hopkins University

Co-Author2: Stephen McJonathan/GT Vision

Co-Author4: BioSciCon Study Group/Belgrade University, SCG

Co-Author5: BioSciCon Study Group/USA

Co-Author6:

## Public Contact Information:

Nenad Markovic

1.301.610.9130

info@bioscocon.com

At the Innovative Corridor Bio 2005, BioSciCon presented results and potentials of the MarkPap® biomarker-based technology for worldwide cervical cancer control. Based on the results obtained on 2,000 patients, the MarkPap® test proved to be superior (accuracy, sensitivity), less expensive (kit, screening procedure), easy-to-use (simple specimen processing), more productive (faster screening) and better controlled (control slides included), with less liability than conventional Pap test and liquid-based Pap tests. The presence of the biomarker of cellular abnormality visualized as a bright red granular intracellular deposit provides also an advantage for image analysis and telecytology (MarkPap® Digital). The slides may be stained with the MarkPap Kit by a generally trained technician in a small remote laboratory, or a nurse in a doctor's office with customer-friendly kit which contains control slides, search only for "red labeled" abnormal cells on the microscope, capture the images by a digital camera and transmit them into a laboratories with pathologists/cytopathologist for evaluation. The result could be returned within hours. In a pilot study, we assembled an image acquisition module, barcode reader and image acquisition software, image and data transferring and image evaluation modules. The preliminary results obtained on MarkPap slides from the BioSciCon Slide Library showed that during transcontinental transfer of images the quality of images allowed the evaluation to be performed. The optimization of the MarkPap procedure for image analysis application, customization of software and development of MarkPap® Digital are in progress in collaboration with several institutions. The IT technology applied in MarkPap Digital further decreases the cost of Pap test, has a potential to move it in small remote laboratories and doctor's offices and become reality for cytological mass cervical cancer screening worldwide with unprecedented benefit for all women in the world. The test has also potentials to become a low-cost alternative for monitoring of the success of HPV vaccination.